OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
In Memoriam Mahlon R. DeLong (1938–2024)	460
John Michael Walshe (April 24, 1920–October 14, 2022)	150
A Multi‐center Genome‐wide Association Study of Cervical Dystonia	120
X‐Linked Dystonia‐Parkinsonism (“Lubag”) May Present with Peripheral Synucleinopathy	118
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy	106
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia	105
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism	95
Issue Information	92
YY1: A New Gene for Childhood Onset Dystonia with Prominent Oromandibular‐Laryngeal Involvement?	90
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials	86
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 12	84
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease	84
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease	81
Movement Disorders: Volume 40, Number 2, February 2025	80
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters	76
	75
Is Persistent Motor or Vocal Tic Disorder a Milder Form of Tourette Syndrome?	74
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy	71
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure	70
Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [¹⁸F]‐FEMPA PET Study	69
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?	69
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism	68
Measuring Tremor—A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating	65
Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model	63
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia	63

Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait	62
Clinical Utility of ¹⁸F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy	62
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation	61
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease	59
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers	58
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property	58
Mortality of People with Parkinson's Disease in a Large UK‐Based Cohort Study: Time Trends and Relationship to Disease Duration	57
Movement Disorders: Volume 37, Number 9, September 2022	56
Movement Disorders: Volume 36, Number 11, November 2021	56
Obituary for Jan O. Aasly (1950–2022)	56
Author Index	55
Reply to: “Application of the mPSPRS to the Salerno Cohort”	54
October Infographic	54
	54
Effect of Public Interest in Magnetic Resonance Imaging–Guided Focused Ultrasound on Enrolment for Deep Brain Stimulation	53
Reply to: “An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis”	53
Reply to: “Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected”	52
Issue Information	51
Thank you to Reviewers 2022	50
Downbeat Nystagmus in Episodic Ataxia Type 1 Associated with a Novel KCNA1 Mutation	49
Genetic Determinants of Survival in Parkinson's Disease in the Asian Population	48
Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder	47
Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment	47
Stress in Musicians with and Without Focal Dystonia Is Not Reflected in Limbic Circuit Activation	46
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity	46
Combining Skin α‐Synuclein Real‐Time Quaking‐Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease	46
Plant‐Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank	45
Diagnostic and Prognostic Value of External Anal SphincterEMGPatterns in Multiple System Atrophy	45
Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin‐Sensitive Magnetic Resonance Imaging and ¹⁸F‐Fluorodopa‐Positron Emission Tomography	45
Research Priorities on the Role of α‐Synuclein in Parkinson's Disease Pathogenesis	44
Novel In‐Frame FGF14 Deletion Causes Spinocerebellar Ataxia Type 27A: Clinical Response to Deep Brain Stimulation and 4‐Aminopyridine	43
	43
Functional Movement Disorders and Drug‐Induced Movement Disorders	42
Issue Information	42
Re‐emergent Tremor in Parkinson's Disease: Evidence of Pathologic β and Prokinetic γ Activity	41
Oligodendrocyte and Extracellular Matrix Contributions to Central Nervous System Motor Function: Implications for Dystonia	41
In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN‐Related Parkinson's Disease	41
Substantiating the Short Burst Duration in Cortical Myoclonus	41
Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search	41
Exploration of Neurodegenerative Diseases Using Long‐Read Sequencing and Optical Genome Mapping Technologies	41
Patients with Allan‐Herndon‐Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment	41
Cortical Functional Connectivity Changes in the Body‐First and Brain‐First Subtypes of Parkinson's Disease	40
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation	40
The Lows of High Reward: Choking Under Pressure	40
Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double‐Blinded Evaluation	40
De Novo and Dominantly Inherited SPTAN1 Mutations Cause Spastic Paraplegia and Cerebellar Ataxia	39
Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease	39
A Biomarker for Benign Adult Familial Myoclonus Epilepsy: High‐Frequency Activities in Giant Somatosensory Evoked Potentials	38
Tremor and Parkinsonism in Chromosomopathies — A Systematic Review	38
Issue Information	36

July Infographic	36
Secondary Paroxysmal Kinesigenic Dyskinesia with a CASR Mutation	36
A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis	36
Digging into the Unknowns of the Human Genome Sequence: The T2T‐CHM13 Reference Assembly Release	36
The Self‐Administered Screening Questionnaire for Parkinson's Disease‐Associated Psychosis (SASPAP)	36
Neurodegeneration with Brain Iron Accumulation Disorders and Retinal Neurovascular Structure	35
Genetic Determined Iron Starvation Signature in Friedreich's Ataxia	35
Reply to: “Early Onset Nonprogressive Generalized Dystonia Is Caused by Biallelic SHQ1 Variants”	35
Movement Disorders: Volume 40, Number 3, March 2025	35
Corrections to “A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design”	35
Spatial Covariance of Cholinergic Muscarinic M₁/M₄ Receptors in Parkinson's Disease	34
Tract‐Specific Spinal Cord Diffusion Tensor Imaging in Friedreich's Ataxia	34
Essential Tremor Suppression with a Novel Anti‐Tremor Orthosis: A Randomized Crossover Trial	34
Association between the Amplification Parameters of the α‐Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease	33
A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ‐009	33
Genotype–Phenotype Correlations for ATX‐TBP (SCA17): MDSGene Systematic Review	33
Static Posture Instability as a Sensitive Biomarker for Motor Abnormalities in Pre‐ataxic Spinocerebellar Ataxia Type 3 Patients	33
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review	33
COVID‐19 Infection Enhances Susceptibility to Oxidative Stress–Induced Parkinsonism	33
Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease	33
Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease	33
August Infographic	32
Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease	32
Clearing the Smoke: What Protects Smokers from Parkinson's Disease?	32
Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis	32
Altered Spatiotemporal Dynamics of the Resting Brain in Mild Cognitive Impairment with Lewy Bodies	32
A Novel SPAST Mutation Results in Spastin Accumulation and Defects in Microtubule Dynamics	32
Teaching an Old Drug a New Trick for Dystonia	31
Movement Disorders: Volume 38, Number 12, December 2023	31
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy	31
Chromatic Pupillometry in Isolated Rapid Eye Movement Sleep Behavior Disorder	31
Paroxysmal Kinesigenic Dyskinesia Secondary to Brain Calcification with a Homozygous MYORG Mutation	31
Whole‐Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy	31
Parkinsonisms	31
Defining the Importance of Minor Hallucinations in Parkinson's Disease	30
Issue Information	30
Practically Defined Off‐State Dyskinesia Following Repeated Intraputamenal Glial Cell Line–Derived Neurotrophic Factor Administration	30
Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease	30
Letter to the Editor: Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia—The SPASTOX Trial	30
Free‐Water Imaging in Friedreich Ataxia Using Multi‐Compartment Models	30
Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid	30
In Memoriam Gregor K. Wenning (1964–2024)	30
Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease	30
Issue Information	29
Epigenetic Drug Effects in Levodopa‐Treated Patients with Parkinson's Disease	29
Correction to “Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus”	29
February Infographic	29
Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review	29
Pain in Multiple System Atrophy: A Community‐Based Survey	29
¹⁸F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies	29
Issue Information	28
Unusual Age‐Dependent Behavior of Leukocytes Telomere Length in Friedreich's Ataxia	28
Putaminal y‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease	28
Potential Disease‐Modifying Effects of Ganglioside GM1 Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel‐Group, Double‐Blind, Randomized, Controlled Trial	28
Ethnic Differences in Dystonia Prevalence and Phenotype	27
Pandemic Tic‐like Behaviors Following Social Media Consumption	27
Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice?	27
CAG Repeat Expansion in THAP11 Is Associated with a Novel Spinocerebellar Ataxia	27
Keyword Index	27
Movement Disorders: Volume 38, Number 9, September 2023	27
Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review	27
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study	27
Obituary for Professor Hiroshi Shibasaki	26
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings	26
Learning to Have a Long‐Duration Response	26
Reply to: Rewiring Brains in Parkinson's Disease: The New Era of Brain Stimulation	26
February Infographic	26
Reply to: Heterogeneity of CSF1R‐RD: Genes, Environment, or Both?	26
Investigating the Brain Mechanisms of Externally Cued Sit‐to‐Stand Movement in Parkinson's Disease	25
Reply to: Enhancing Clarity in Tremor Network Gene Expression Analysis	25
Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease	25
Movement Disorders: Volume 39, Number 9, September 2024	25
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study	24
First Evidence for Disease‐Modifying Treatment of SLC20A2‐Related Primary Familial Brain Calcification	24
	24
Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations	24
Reply to: “Reproducibility of Voice Analysis with Machine Learning”	24
Issue Information	24
Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome	23
MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression	23

GNAO1 Haploinsufficiency: The Milder End of the GNAO1 Phenotypic Spectrum	23
No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts	23
The Concept of Motor Reserve in Parkinson's Disease: New Wine in Old Bottles?	23
Two London Memorials to “James Parkinson [1755–1824], Esq. Surgeon, Late of Hoxton‐Square”	23
Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18‐Year Study	23
Proteomic Profiling in Dystonia: The Next Frontier for Pathophysiology Research and Biomarker Exploration	23
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease	22
Diffusion Tensor Imaging‐Along the Perivascular‐Space Index Is Associated with Disease Progression in Parkinson's Disease	22
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease	22
The Gastrointestinal Dysfunction Scale for Parkinson's Disease	22
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels	22
Expanding the Allelic and Clinical Heterogeneity of Movement Disorders Linked to Defects of Mitochondrial Adenosine Triphosphate Synthase	22
Automated Motor Tic Detection: A Machine Learning Approach	22
Cellular Prion Protein Mediates α‐Synuclein Uptake, Localization, and Toxicity In Vitro and In Vivo	22
Long‐Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia	21
Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut	21
Multimodal Analysis of the Visual Pathways in Friedreich's Ataxia Reveals Novel Biomarkers	21
Mutation Screening of TFG in α‐Synucleinopathy and Amyotrophic Lateral Sclerosis	21
	21
On‐Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial	21
Longitudinal Clinical and Biological Characteristics in Juvenile‐Onset Huntington's Disease	21
Striatal Cholinergic Dysregulation after Neonatal Decrease in X‐Linked Dystonia Parkinsonism‐Related TAF1 Isoforms	21
Automated Quantification of Eye Tics Using Computer Vision and Deep Learning Techniques	21
	21
Where Do Parkinson's Disease Patients Look While Walking?	21
	20
March Infographic	20
Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?	20
The Pain in Dystonia Scale (PIDS)—Development and Validation in Cervical Dystonia	20
Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes	20
Movement Disorders: Volume 38, Number 11, November 2023	20
mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis	20
Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility?	20
Issue Information	20
Keyword Index	20
A Short Progressive Supranuclear Palsy Quality of Life Scale: Data from the PSP‐NET	20
Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome	19
Step Width Haptic Feedback for Gait Stability in Spinocerebellar Ataxia: Preliminary Results	19
Diagnosis and Outcomes of Late‐Onset Wilson's Disease: A National Registry‐Based Study	19
Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review	19
Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell‐Derived A9 Dopaminergic Neurons	19
April Infographic	19
Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients	19
Prasinezumab: A Bayesian Perspective on Its Efficacy	19
Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease	19
Deep Brain Stimulation Improves Parkinson's Disease‐Associated Pain by Decreasing Spinal Nociception	19
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof‐of‐Principle Issues from a Randomized Controlled Study	19
Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons	19
Pathophysiological Role of Primary Motor Cortex in Essential Tremor	19
Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study	19
Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease	19
Catatonia: What Else Matters?	19
Reply to Letter to the Editor‐MDS‐23‐0498.R2/MDS‐24‐0318.R1	19
Brain Imaging Phenotypes Associated with Polygenic Risk for Essential Tremor	19
Anodal Cerebellar Transcranial Direct Current Stimulation Reduces Motor and Cognitive Symptoms in Friedreich's Ataxia: A Randomized, Sham‐Controlled Trial	18
Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline	18
Erythrocytic α‐Synuclein and the Gut Microbiome: Kindling of the Gut‐Brain Axis in Parkinson's Disease	18
Movement Disorders: Volume 36, Number 10, October 2021	18
A 10‐Year Community‐Based Study of Leucine‐Rich Repeat Kinase 2 G2385R Carriers' Conversion to Parkinson's Disease	18
Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication‐Refractory Parkinson's Disease Tremor	18
Viewpoint on Milestones for Fellowship Training in Movement Disorders	18
Surgery Imaging and Technology	18
Advancing Parkinson's Research: Considerations and Future Directions	18
Issue Information	18
Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease	18
An Exponential Rather Than Multistep Model of Parkinson's Disease Pathogenesis	18
Computerized Cognitive Training Increases Gray Matter Volumes in Huntington's Disease: A Pilot Study	18
The Dawn of Precision Medicine for Deep Brain Stimulation in Parkinson's Disease?	18
Genetic Analysis of GCA Repeats in the GLS Gene: Implications for Undiagnosed Ataxia and Spinocerebellar Ataxia 3 in Mainland China	17
A GNAI1 Pathogenic Variant in a Case with GNAO1‐Isolated Dystonia: A Modifier of Disease Severity?	17
IRF2BPL‐Related Disorder, Causing Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech and Seizures (NEDAMSS) Is Characterized by Pathology Consistent	17
Cross‐Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease	17
Disentangling the Connection Between Neurodevelopment and Neurodegeneration in Huntington's Disease	17
Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease	17
Globus Pallidus Internus (GPi) Neuromodulation is Not Effective in Unverricht–Lundborg Disease to Control Myoclonia	17
Clinical Utility of Neurophysiologic Classification (and Declassification) of Myoclonus	17
Reply to: “A Primary Writing Tremor Is a Form of Dystonic Tremor: Is the Debate Settled?”	17
Further Directions in Mindfulness‐Based Interventions for Tic Disorders	17
Aggregation‐Seeding Forms of α‐Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid	17
No Association Between Rare TWNK Variants and Parkinson's Disease in European Cohorts	17
Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients	17
Neurodevelopmental Gene‐Related Dystonia‐Parkinsonism with Onset in Adults: A Case with NAA15 Variant	17
Reply to: Comment on De Giorgis et al. “Randomized Phase 3 Study of Triheptanoin for Glut1 Deficiency Syndrome–Associated Paroxysmal Movement Disorders”	17
High Pesticide Exposure Events and Dream‐Enacting Behaviors Among US Farmers	16
Redefining Bradykinesia	16
Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus	16
Shaking Up Ataxia: FGF14 and RFC1 Repeat Expansions in Affected and Unaffected Members of a Chilean Family	16
Beta Burst Characteristics and Coupling within the Sensorimotor Cortical‐Subthalamic Nucleus Circuit Dynamically Relate to Bradykinesia in Parkinson's Disease	16
Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PD	16
Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance–Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study	16
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy	16
Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome	16
Diffusion Magnetic Resonance Imaging Microstructural Abnormalities in Multiple System Atrophy: A Comprehensive Review	16
Bilateral Simultaneous Magnetic Resonance–Guided Focused Ultrasound Pallidotomy for Life‐Threatening Status Dystonicus	16
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study	16